NASDAQ:BIOL BIOLASE (BIOL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About BIOLASE Stock (NASDAQ:BIOL) Get BIOLASE alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume2.58 million shsMarket Capitalization$581 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BIOLASE, Inc. was a medical technology company focused on developing, manufacturing and marketing laser systems for dentistry. Its products were designed to support a range of soft-tissue and hard-tissue procedures, including minimally invasive treatments, periodontal therapy, restorative dentistry and oral surgery. The company’s principal product line was Waterlase, a dental laser system that uses a combination of laser energy, water and air to perform certain procedures. BIOLASE also offered the Epic family of diode lasers, which were used primarily for soft-tissue procedures, teeth whitening and other dental applications. Related products included accessories, consumables, software and training and support services for dental professionals. Founded in 1987, BIOLASE served dental practices and other oral-health providers through direct sales and distributors in the United States and international markets. The company was historically headquartered in California and traded on the Nasdaq under the symbol BIOL. BIOLASE entered bankruptcy proceedings in 2023, and subsequent restructuring and asset-sale activity affected the company’s operations and corporate status.AI Generated. May Contain Errors. Read More Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOL Stock News HeadlinesBIOLASE and MegaGen America Expand Waterlase Foundations Training to Three U.S. Education CentersAugust 20, 2026 | tmcnet.comBIOLASE and MegaGen America Launch U.S. Commercial Collaboration to Advance "More Brilliant Dentistry Together"July 22, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California FacilityJune 25, 2026 | prnewswire.comBIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025November 25, 2025 | finance.yahoo.comBIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025October 14, 2025 | prnewswire.comBIOLASE MG LLC: BIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen ImplantSeptember 10, 2025 | finanznachrichten.deBIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen ImplantSeptember 10, 2025 | prnewswire.comSee More Headlines BIOL Stock Analysis - Frequently Asked Questions How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings data on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, topping analysts' consensus estimates of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative net margin of 41.65% and a negative trailing twelve-month return on equity of 1,782.73%. When did BIOLASE's stock split? Shares of BIOLASE reverse split on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN). Company Calendar Last Earnings11/10/2021Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees160Year Founded1987Profitability EPS (Trailing Twelve Months)($14.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.63 million Net Margins-41.65% Pretax Margin-41.56% Return on Equity-1,782.73% Return on Assets-55.31% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.36 Sales & Book Value Annual Sales$48.83 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares33,407,000Free Float33,317,000Market Cap$581 thousand OptionableNot Optionable Beta0.67 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BIOL) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredAI Panic: Sell now or wait?Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock...TradeSmith | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
